Related Experiment Videos
Ziprasidone in Huntington's disease: the first case reports.
Raphael M Bonelli1, Brigitte M Mayr, Gerald Niederwieser
1University Clinic of Psychiatry, Karl Franzens University Graz, Austria. raphael.bonelli@klinikum-graz.at
Journal of Psychopharmacology (Oxford, England)
|February 12, 2004
Summary
Huntington's disease (HD) patients experienced motor improvements with ziprasidone, an atypical antipsychotic. This study suggests ziprasidone may effectively manage choreiform hyperkinesias in HD patients.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Huntington's disease (HD) is a progressive, autosomal dominant neurodegenerative disorder.
- Choreiform hyperkinesias in HD are typically managed with classical antipsychotics.
- Atypical antipsychotics, like ziprasidone, have not been extensively studied for HD treatment.
Observation:
- Three genetically confirmed HD patients were treated with ziprasidone.
- Patients were assessed using the Unified Huntington's Disease Rating Scale (UHDRS).
Findings:
- Ziprasidone treatment led to significant improvements in motor function across several UHDRS categories.
- This indicates a potential therapeutic benefit of ziprasidone in managing HD motor symptoms.
Implications:
- Ziprasidone shows promise as a novel treatment option for choreiform hyperkinesias in Huntington's disease.
- Further clinical trials are warranted to confirm the efficacy and safety of ziprasidone for HD management.